Annual epidemics of human influenza A and, more variably, influenza B virus infections cause significant amounts of morbidity, economic losses and mortality in the general population [1] . Among recently circulating influenza A viruses, those of the H3N2 subtype have been particularly associated with increases in both morbidity and mortality. In addition, when pandemic influenza occurs due to emergence of a novel type A influenza virus [2] , the effects on public health and the economy might be far beyond that of annual epidemics. Immunization of susceptible populations is the principle strategy for protection against both epidemic and pandemic influenza. Two classes of antiviral agents are also available for prevention and treatment of influenza, namely, the adamantanes or M2 ion channel blockers, amantadine and rimantadine, and the neuraminidase inhibitors (NAIs), zanamivir and oseltamivir. In the setting of a major influenza epidemic or pandemic for which vaccine is unavailable, antivirals could reduce morbidity and mortality, given that sufficient amounts were available and deployed rapidly for use [2] [3] [4] . Many countries have Introduction created reserves of NAIs, particularly oseltamivir and sometimes zanamivir, and less often of adamantanes for this purpose, and some have used them in the context of the current H1N1 pandemic.
One of the key concerns with regard to wide-scale use of influenza drugs in the population is the emergence of antiviral drug resistance. Amantadine and rimantadine are effective only against type A influenza viruses, and fully transmissible resistant variants emerge readily during therapeutic use [5, 6] . Furthermore, beginning with the 2003-2004 season in the northern hemisphere, global circulation of resistant A(H3N2) variants harbouring a Ser31Asn mutation in the M2 protein has rendered this class of antivirals unreliable [7, 8] . More recently, adamantane-resistant A(H1N1) variants with this same mutation have also been increasingly detected [9, 10] and the current pandemic H1N1 strain already exhibited adamantane resistance when it was first detected in humans [11] .
These resistant variants have circulated in the absence of continuing selective drug pressure and appear at least as transmissible as susceptible wild-type viruses.
The NAIs are inhibitory against both type A and B influenza viruses and are associated with less frequent detection of drug-resistant variants in treated individuals than are the adamantanes [12, 13] . Unlike adamantane-resistant variants, those resistant to NAIs usually appear to be biologically impaired in laboratory studies [14, 15] . Recent monitoring of NAI susceptibility in community isolates of influenza viruses by the Neuraminidase Inhibitor Susceptibility Network (NISN) found no significant increase of circulating NAI-resistant viruses during the first 3 years after their licensure [16] . However, the use of oseltamivir has increased dramatically in Japan since its licensure in 2001 and during the 2004-2005 season reached the highest levels of population coverage documented to date ( Figure 1) . Furthermore, the frequency of detecting drug-resistant mutants in oseltamivir-treated children appears to be higher than previously reported [17, 18] . These circumstances led NISN to undertake surveillance for NAI susceptibility among community epidemic isolates collected during the 2003-2007 influenza seasons in Japan, in order to determine whether increased oseltamivir use was associated with emergence and transmission of NAI-resistant variants in the community. The results reported here, as well as those from 3 years surveillance carried out previously by the NISN [16, 19] [20, 21] , there was no evidence of these resistant viruses circulating in Japan in the preceding 2006-2007 season and no evidence of sustained decreases in susceptibility to NAIs in influenza A or B viruses over this period.
Methods

Viruses and cells
Clinical isolates of influenza A and B viruses were recovered from ambulatory and hospitalized patients by sentinel clinics and hospitals from September 2003 to June 2007. The specimens were collected before the patients were prescribed any drugs. Although none of the isolates came from patients known to have received oseltamivir treatment, it was not possible [27] .
A B
to determine whether the patients were exposed to contacts on oseltamivir treatment. The viruses used in this study were provided to the National Institute of Infectious Diseases (NIID; Tokyo, Japan) by municipal and prefectural public health institutes across Japan. A random selection of approximately 10% of the original isolates were used for these studies. The total number of isolates and the relative frequency of influenza A(H1N1), A(H3N2) and B viruses tested varied from across the seasons (Table 1 ). Typing and subtyping was done using a haemagglutination inhibition assay. In addition, sequence analysis of the HA and NA genes was done for almost all viruses received by the NIID. Initial isolation was performed in Madin-Darby canine kidney (MDCK) cells. For expansion of virus isolates for NAI assay, MDCK cells were subcultured in phenol red-free Eagle's minimum Essential medium (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS; Summit Biotechnology, Fort Collins, CO, USA), 1 mM l-glutamine, 1% HEPES and 1% penicillin-streptomycin (all from Gibco). Virus growth medium containing 0.14% bovine serum albumin fraction V instead of FBS, and 2.5 µg/ml of tosylsulfonyl phenylalanyl chloromethyl ketone-trypsin (Worthington Biochemical Co., Lakewood, NJ, USA) was used for virus growth. Initial isolation was done by NIID and expansion of isolates was performed at Viromed Laboratories (Minnetonka, MN, USA).
Drugs and NAI susceptibility assays
Several different assay methods were used to test susceptibility and confirm resistance (Table 2) . In all assays, samples were all pre-titrated prior to the inhibition assay, to determine an amount of virus to use that was in the linear portion of the activity curves. Susceptibility to oseltamivir carboxylate and zanamivir was examined initially in a previously described chemiluminescent (CL) enzyme inhibition assay [19, 22] , using neuraminidase (NA)-star (Tropix, Bedford, MA, USA) as the substrate [23] . Between 1996 and 2005, screening assays were performed by Viromed Laboratories on masked samples, and the values were reported as the drug concentrations required to inhibit enzyme activity by 50% (IC 50 In addition to the phenotypical data from the NAI assays, the frequency of known resistance mutations was also determined by analysis of sequence data from the World Health Organization Collaborating Center for Reference and Research on Influenza in the NIID and from the National Institute of Technology and Evaluation (NITE) laboratories (Tokyo, Japan; Table  2) 
Time-series study for influenza B susceptibility
The drug sensitivity of 500 randomly selected influenza B isolates from 2000-2006 was tested against both oseltamivir carboxylate (provided by Keith Watson, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia) and zanamivir (provided by Margaret Tisdale, GlaxoSmithKline) to determine whether any significant changes in IC 50 values were seen in isolates from different years tested in the same assay. Each assay batch contained comparable proportions of isolates from every season. These assays were conducted with the MUNANA-based fluorescent (FL) NAI assay (Table 2 ) [26] , in the laboratory of JLMB.
Data analyses
Previously described methods were used to identify isolates with high IC 50 values for further phenotypical testing and sequence analysis [16] . Because IC 50 values are not normally distributed, values underwent log 10 transformation for analysis. Robust data analyses (box and whisker plots) were used to identify extreme IC 50 values. Two types of outliers were defined, mild (between 1.5 and 3.0× the interquartile range from the 25th and 75th percentiles) and extreme (>3.0× the interquartile range from the 25th and 75th percentiles and at least 10-fold higher than the mean IC 50 ). All known resistant variants were extreme outliers.
To assess whether changes in the NAI susceptibility among influenza A(H3N2) and A(H1N1) or B viruses had occurred since the introduction of the drugs into Japan, we also compared the results with those obtained from our previous analysis of isolates during the influenza seasons from 1996 to 2003 [16, 19] . The subsets of Japanese data were taken from the total data sets used in the prior publications for the 3 years before (1996-2000) [19] and after (2000-2002) [16] approval of the drugs in Japan.
Results
Neuraminidase inhibitor usage in Japan
In Japan, the capsule form of oseltamivir is prescribed for adult and juvenile patients with a body weight ≥37.5 kg, and the paediatric suspension syrup can be prescribed in children as young as 1 year old. As shown in Figure 1A , the estimated number of oseltamivir treatment courses has been increasing since its introduction in February 2001 [27] . Overall, >6 million treatment courses in Japan were prescribed during the 2003-2004 season and >10 million during the following season. Approximately 70% of this amount was oseltamivir capsules and approximately 30% was the paediatric suspension ( Figure 1B ) [27] . Zanamivir use was much less during this period and averaged <200,000 courses annually. [19] . b Japanese subset from Monto et al. [16] . NA amino acid sequences were determined for the extreme outliers of the A(H3N2) viruses, as well as for 5 mild outliers and 6 other isolates of A(H3N2) viruses and for 8 mild outliers of influenza B viruses. None of the mild outliers had mutations in their NA genes known to be associated with oseltamivir resistance. By contrast, previously recognized nucleotide substitutions and associated amino acid substitutions conferring oseltamivir resistance [13] (Table 3 ). The median zanamivir IC 50 values for A(H3N2), A(H1N1) and influenza B NAs were 2.3 nM, 1.2 nM and 3.1 nM, respectively (Table 3) . Among the A(H3N2) viruses examined, none were recognized as resistant in the CL NAI assay, and only one was categorized as a mild outlier. Similarly, none of 60 A(H1N1) viruses was found to be resistant. Two of 58 influenza B isolates were mild outliers to both drugs, and sequence analysis identified a known resistance mutation in one of them, namely D197N [25, 28] . Sequence analysis of 223 influenza B isolates did not identify any additional isolates with known resistance mutations (Table 4) , and testing of a further discrete 97 influenza B isolates in the time series study (FL NAI assay) also did not detect phenotypical resistance (Table 5) . 
Virus isolation patterns
2005-2006 Season
Sequence analysis of 250 influenza A(H3N2) and 61 influenza B isolates did not identify any viruses with known resistance mutations (Table 4) , nor were any resistant influenza B isolates identified from the additional 58 viruses tested in the time series experiment (Table 5) . By contrast, 4 (3%) of 132 A(H1N1) viruses possessed an H274Y (H275Y in N1 numbering system) mutation known to confer high-level oseltamivir resistance in N1-containing viruses [29, 30] . These isolates were confirmed as phenotypically resistant to oseltamivir by the CL NAI assay, with IC 50 values for oseltamivir ranging from 122 to 464 nM and for zanamivir from 2.9 to 6.7 nM. All samples were also subsequently tested in the CL NAI assay by the NIID, but no additional resistant isolates were detected (data not shown). 50 values were observed in some years, there was no sustained decrease in susceptibility to either drug over the 6 year period ( Table 5 
2006-2007 Season
Discussion
In recent influenza seasons, Japan has had the highest per capita use of oseltamivir in the world (Figure 1 10% of the population. These levels of drug use greatly exceed those anticipated in most countries during pandemic influenza and approach those in many countries that have developed or are developing oseltamivir stockpiles. Increasing use of oseltamivir in Japan, the recent reports of oseltamivir-resistant variants emerging in 16-18% of oseltamivir-treated children [17, 18] , and evidence for transmissibility of some NAI-resistant variants in animal models [14] and in households [31] raised concerns about the potential appearance and transmission of NAI-resistant viruses in the community at large. Consequently, NISN undertook an investigation of large numbers of community isolates in Japan starting with the 2003-2004 influenza season to look for evidence of oseltamivir resistance emergence and spread at the community level. Our results to 2007 indicate that NAI resistance was encountered at low levels in community isolates, and the overall prevalence of circulating resistant strains recognized in this study does not appear to have increased substantially compared with that obtained in our earlier study encompassing the 1999-2002 seasons in Japan (Table 3 ) [16] .
We found evidence for apparent community transmission of oseltamivir-resistant viruses during several [20, [32] [33] [34] , and were subsequently detected at high frequency in the southern hemisphere, including 100% of A(H1N1) isolates in South Africa [20] and in the 2008-2009 winter >98% of H1N1 isolates were resistant.
There is no evidence to indicate this high level of resistance in A(H1N1) viruses arose because of the high use of oseltamivir in Japan. Indeed, although H1N1 viruses were predominant in Japan in 2007-2008, only 45 (2.6%) of a total of 1,734 isolates examined were resistant [20] . Among these resistant H1N1 viruses, one resistant virus (clade 2C) was found in the early phase of that season, which was considered a spontaneous mutant. Subsequently in early 2008, 26 'Hawaii'-lineage-resistant H1N1 viruses of clade 2B were identified. These occurred in 9 prefectures but clustered in 2 prefectures out of the 9 prefectures (10 and 4 viruses, respectively). These viruses might have been introduced into Japan from outside, probably from Hawaii, and spread to an extent in these areas. Finally, during the late 2007-2008 season, 18 'European' lineage mutants were found in 3 prefectures. Although the percentage of the lineage virus was 2.6% of total H1N1 in Japan, it was 32% in a prefecture affected by the virus, and some mutants were also isolated in surrounding prefectures. This indicated that the H1N1 resistant virus was introduced into Japan and spread significantly in a localized area.
The continued circulation of oseltamivir-resistant A(H1N1) viruses has occurred in the apparent absence of selective drug pressure, and their global spread demonstrates that these recent oseltamivir-resistant A(H1N1) with H274Y variants are efficiently transmitted from person to person. Earlier studies of A(H1N1) and A(H5N1) variants with the H274Y mutation reported variable reductions in replication fitness in vitro and in ferrets [35, 36] , although a clinical isolate of an A(H1N1) virus with this mutation was transmissible between ferrets [14] and another A(H5N1) virus with this mutation was able to replicate and cause a lethal infection in mice [37] .
To our knowledge, in the current study, the patients with the resistant viruses were not treated with oseltamivir before the specimens were taken for virus isolation. Unfortunately, no further clinical and epidemiological data were available, so that it is unknown whether they might have been exposed to oseltamivirtreated patients. Consequently, the resistant variants possibly represented primary resistance or were transmitted from an oseltamivir-treated patient. No primary drug resistance was recognized in influenza viruses before the introduction of oseltamivir in surveillance studies [19, 38] or in large numbers of isolates collected in prospective treatment studies [39] [40] [41] . However, we cannot exclude that a low level of resistant variants occurs in circulating viruses in the absence of selective pressure. It is clear, however, that the H3N2 resistant variants were not related to each other because of geographical scattering of the places of isolation (Tokyo, Fukuoka and Okayama). Tokyo is in the centre of Japan, whereas Fukuoka is approximately 1,000 km west and Okayama is located between the two cities. In addition, the three resistant A(H3N2) viruses belonged to at least two different sublineages of NA by phylogenetic analysis.
The more likely explanation is that the resistant viruses found in this study represented transmission from an oseltamivir-treated patient to a close contact. In contrast to the experience observed with the M2 inhibitor rimantadine [5] , no resistance emergence or transmission was detected in household-based studies of oseltamivir or zanamivir treatment and postexposure prophylaxis [42, 43] . Animal model studies indicate that oseltamivir-resistant A(H3N2) variants possessing a R292K substitution are less infectious and transmissible in ferrets, compared with its wildtype parents [14, 44] . By contrast, another oseltamivirresistant A(H3N2) variant caused by E119V substitution is fully replication competent and transmissible in ferrets [14, 15, 44] . Of note, in the guinea pig model an A(H3N2) virus with this mutation was transmissible by direct contact but not by aerosol, in contrast to the wild-type [45] . Therefore, because no resistance was seen in community isolates prior to the introduction of the NA inhibitors, the detection of viruses in untreated patients with the E119V, R292K and H274Y mutations would be more consistent with transmission from an oseltamivir-treated contact in whom the resistance arose, rather that from spontaneous emergence in the untreated patient.
In addition to screening for resistant variants, our studies also looked for changes in oseltamivir susceptibility over time to detect smaller decrements in sensitivity related to its increasing use. For influenza A(H3N2) and A(H1N1) viruses we found no substantial changes in susceptibility over time, following introduction of the NAIs into clinical practice to 2005 (Table 3) . For influenza B viruses, we confirmed their lower susceptibility to oseltamivir compared with influenza A viruses [16, 19] , but also noted some season-to-season variation in IC 50 values for both oseltamivir carboxylate and zanamivir (Table 5) . Recent studies from Japan [46] and the United Kingdom (MZ, unpublished observations) reported some season-to-season variation in oseltamivir susceptibility among community isolates of influenza B viruses, but no sustained pattern of decreased susceptibility to NAIs . Another study of predominately North American B isolates found no important differences in oseltamivir IC 50 values across three seasons from 2004-2007 [34] . Of note, the Japanese study [46] used an FL NAI assay, in which the influenza B NAs are known to have higher IC 50 values compared with the CL NAI assay [19, 22] . Their reported mean IC 50 for oseltamivir was 75.4 nM for 193 influenza B isolates, or approximately 250-fold less susceptible to oseltamivir compared with influenza A(H3N2) viruses. This compares to a mean IC 50 in our time series of 25-35 nM for oseltamivir carboxylate and of 2-4 nM for zanamivir (Table 5 ). Various parameters including buffer, pH and substrate concentration can affect the IC 50 (JLMB, unpublished observations) [47] , which could account for their higher IC 50 compared with those obtained here. Of note, the lower susceptibility of influenza B viruses seen in both the FL and CL NAI assays relative to influenza A NAs might account for the slower clinical and virological responses to treatment in young children [46] and prophylaxis failures in immunocompromised hosts [28] . Continued monitoring of influenza B susceptibility is therefore essential.
In the setting of a pandemic or major epidemic caused by a virus with a poor antigenic match to available vaccines, NAIs could play an important role in the initial response until sufficient vaccines were available [2] [3] [4] . Currently, many countries are developing stockpiles of oseltamivir and other antivirals for such a threat. Given first exposure to a novel virus, the emergence of resistant viruses from NAItreated patients might be expected to be higher in an immunologically naive population than observed in the interpandemic period in those with some degree of pre-existing immunity. The frequencies of resistance emergence in young children might be more indicative of those expected in pandemic disease, and these have been up to 80% for amantadine [48] and 16-18% for oseltamivir [17, 18] in paediatric studies to date. Zanamivir resistance emergence in this target population has not been adequately examined, in part because the current Diskhaler device cannot be reliably used below age 5 years. The principle public health concerns are whether such variants are readily transmissible and capable of causing disease. Both household and, more recently, global transmission [7] [8] [9] [10] of amantadine-resistant A(H3N2) and, to a lesser extent, A(H1N1) variants have been documented. Although we found that the risk of resistance emergence appears to be less with oseltamivir use, the recent experience with widespread circulation of oseltamivir-resistant A(H1N1) viruses since the 2007-2008 season illustrates the unpredictability of influenza virus epidemiology [20, 21, 32, 33] . One mathematical modelling study [49] predicted little community spread of NAI-resistant variants when they were associated with small decrements in transmissibility, and the importance of transmission fitness as a risk factor in spread of resistant variants has been confirmed in other models of pandemic influenza [50, 51] . Thus, continued surveillance during both epidemic and pandemic periods is crucial to monitor for the transmission of NAI-resistant viruses in order to understand optimal usage of antivirals and to make informed decisions regarding diversification and deployment of stockpile contents. governments in Japan through the National Influenza Surveillance Program.
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